Xcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves ...

The new data from the PERSEUS and CEPHEUS studies show that Darzalex Faspro®-based regimens achieve up to 95% 4-year PFS and ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

The Phase 3 AMPLITUDE trial showed that adding niraparib to abiraterone acetate and prednisone reduced radiographic ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

The FDA approved darolutamide (Nubeqa®) for metastatic castration-sensitive prostate cancer, based on the Phase III ARANOTE ...

The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death ...

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

The first-in-human results for pasritamig, a bispecific T-cell engager, show promising Phase 1 data in heavily pretreated ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...